AKAvinash Kaur

Avinash Kaur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Avinash Kaur has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Monitoring Pathogenic Viable E. coli O157:H7 in Food Matrices Based on the Detection of RNA Using Isothermal Amplification and a Paper-Based Platform

    by Sabrina Petrucci, Connor Costa, David Broyles, Avinash Kaur, Emre Dikici, Sylvia Daunert, Sapna K. Deo

    In recent years, the number of product recalls and contamination incidents involving pathogenic bacteria has significantly increased, and the ensuing infections continue to be an ongoing problem for public health and agriculture. Due to the widespread impact of these pathogens, there is a critical need for rapid, on-site assays that can provide rapid results. In this work, we demonstrate the development of a rapid and simple test based on the combination of reverse transcription with recombinase polymerase amplification followed by lateral flow strip detection of viable Escherichia coli O157:H7 cells by detecting the RNA of the pathogen. The optimized method can be performed for approximately 2 h with a detection limit of 10 CFU/mL of E. coli O157:H7 in buffer, spinach, and ground beef samples. Our assay is sensitive, detecting only E. coli O157:H7 and not nonpathogenic E. coli or other similar pathogens. This strategy was able to distinguish viable from nonviable bacteria and more significantly was able to detect viable but nonculturable bacteria, which is a major issue when using culture-based methods for monitoring pathogenic bacteria. An important advantage of this test is that it can provide timely identification and removal of contaminated consumables prior to distribution without an extensive sample preparation.


  • Selectively targeting disease‐restricted secretogranin III to alleviate choroidal neovascularization

    by Liyang Ji, Prabuddha Waduge, Lili Hao, Avinash Kaur, Wencui Wan, Yan Wu, Hong Tian, Jinsong Zhang, Keith A. Webster, Wei Li

    Choroidal neovascularization (CNV), a leading cause of blindness in the elderly, is routinely treated with vascular endothelial growth factor (VEGF) inhibitors that have limited efficacy and potentially adverse side effects. An unmet clinical need is to develop novel therapies against other angiogenic factors for alternative or combination treatment to improve efficacy and safety. We recently described secretogranin III (Scg3) as a disease‐selective angiogenic factor, causally linked to diabetic retinopathy and acting independently of the VEGF pathway. An important question is whether such a disease‐selective Scg3 pathway contributes to other states of pathological angiogenesis beyond diabetic retinopathy. By applying a novel in vivo endothelial ligand binding assay, we found that the binding of Scg3 to CNV vessels in live mice was markedly increased over background binding to healthy choriocapillaris and blocked by an Scg3‐neutralizing antibody, whereas VEGF showed no such differential binding. Intravitreal injection of anti‐Scg3 humanized antibody Fab (hFab) inhibited Matrigel‐induced CNV with similar efficacy to the anti‐VEGF drug aflibercept. Importantly, a combination of anti‐Scg3 hFab and aflibercept synergistically alleviated CNV. Homozygous deletion of the Scg3 gene markedly reduced CNV severity and abolished the therapeutic activity of anti‐Scg3 hFab, but not aflibercept, suggesting a role for Scg3 in VEGF‐independent CNV pathogenesis and therapy. Our work demonstrates the stringent disease selectivity of Scg3 binding and positions anti‐Scg3 hFab as a next‐generation disease‐targeted anti‐angiogenic therapy for CNV.


  • Open Access

    Levels of TGF-β1 in peri-miniscrew implant crevicular fluid

    by Avinash Kaur, Om Prakash Kharbanda, Moganty R. Rajeswari, Dinesh Kalyanasundaram